Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
Iran's Revolutionary Guard says it seized a British tanker in the Strait of Hormuz, claiming it failed to follow international marine regulations.World Newsread more
More than a quarter of the S&P 500 companies report earnings in the week ahead, and that could buffet the market as investors await the Fed's meeting at the end of the month.Market Insiderread more
Walmart is making further organizational changes as it continues to integrate its store and digital operations and leadership, according to a memo obtained by CNBC that was...Retailread more
George Nader helped arrange a January 2017 meeting in the Seychelles between Erik Prince and the head of Russia's sovereign wealth fund, who reported directly to Vladimir...Politicsread more
These are the stocks posting the largest moves midday.Market Insiderread more
"I'm not hearing people blame the Fed as much as they're blaming tariffs," says CNBC's Jim Cramer.US Economyread more
Earlier, Williams said in a speech that "it's better to take preventative measures than to wait for disaster to unfold."The Fedread more
Four members of the House Armed Services Committee, including ranking member Rep. Mac Thornberry, R-Texas, said moving forward with the contract was critical to U.S. national...Technologyread more
(Feb.1)@ (Corrects paragraph 7 to remove reference to dosage)
Feb 1 (Reuters) - An injection to treat forehead wrinkles is set to rival Allergan's Botox after U.S. regulators approved Evolus Inc's cheaper treatment on Friday, sending its shares up about 5 percent after the bell.
The approval of Evolus's Jeuveau to treat frown lines comes about eight months after the agency declined to approve the drug, citing deficiencies related to the chemistry and manufacturing of the product. "We see Evolus' entry into this market as very disruptive," Evolus Chief Executive Officer David Moatazedi said in an interview prior to the FDA's decision.
Evolus expects Jeuveau to be priced between 20 and 25 percent lower than Botox and is likely to be available throughout the United States at physician offices starting Spring 2019, the company said.
While Botox is expected to face challenges for its therapeutic uses from rival treatments, its cosmetic uses have so far remained largely unchallenged.
Botox was launched in 2002 and over the years it has evolved from a cosmetic injection to a treatment for migraines and bladder dysfunction, bringing in $3.58 billion in sales for Allergan in 2018.
Alternatives to Botox such as anti-wrinkle injections like Nestle's Dysport or Merz Pharma's Xeomin have failed to achieve Botox's success.
As it prepares to face competition, Allergan said https://in.reuters.com/article/us-allergan-aesthetics/allergan-says-revenue-from - a e s t h e t i c s - u n i t - m a y - d o u b l e - b y - 2 0 2 5 - i d I N K C N 1 L U 1 Z W last year it was planning to double its spending on direct-to-consumer advertising and to expand its Botox sales force.
Newark, California-headquartered Revance Therapeutics is also developing a rival to Botox, which could have longer effect in treating wrinkles.
"The combination of Allergan doubling their investment in advertising for Botox, the under-penetration of the consumer category...our entry with Jeuveau will attract a significant amount of interest not just with the doctor ... but also for consumers," Moatazedi said. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar and Arun Koyyur)